sufotidine sufotidine sufotidine (inn, usan, codenamed ah25352) is a long-acting competitive h2 receptor antagonist which was under development as an antiulcerant by glaxo (now glaxosmithkline). it was planned to be a follow-up compound to ranitidine (zantac). when taken in doses of 600 mg twice daily it induced virtually 24-hour gastric anacidity thus closely resembling the antisecretory effect of the proton pump inhibitor omeprazole. its development was terminated in 1989 from phase iii clinical trials based on the appearance of carcinoid tumors in long-term toxicity testing in rodents. sufotidineclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status development terminated identifiers iupac name 2-methyl-5-(methylsulfonylmethyl)-n-propyl]-1,2,4-triazol-3-amine cas number80343-63-1pubchem cid71763chemspider64802unii56b0591y76keggd05939comptox dashboard (epa)dtxsid50230254 chemical and physical dataformulac20h31n5o3smolar mass421.56 g·mol−13d model (jsmol)interactive image smiles cn1c(=nc(=n1)cs(=o)(=o)c)ncccoc2=cc=cc(=c2)cn3ccccc3 inchi inchi=1s/c20h31n5o3s/c1-24-20(22-19(23-24)16-29(2,26)27)21-10-7-13-28-18-9-6-8-17(14-18)15-25-11-4-3-5-12-25/h6,8-9,14h,3-5,7,10-13,15-16h2,1-2h3,(h,21,22,23)key:jeykzwrxdalmng-uhfffaoysa-n synthesis